A Comprehensive Review on the Nanocarrier-based Drug Delivery of Cabazitaxel
Abstract
Drug resistance significantly impacts the anticancer activity of several taxane-based formulations, i.e., docetaxel (DTX) and paclitaxel (PTX) formulations in clinical research. Cabazitaxel is a second-generation taxane with high anticancer efficacy than paclitaxel and docetaxel. The structure of cabazitaxel depicts low P-glycoprotein (p-gp) efflux pump affinity, which could help overcome the taxane resistance. Cabazitaxel’s clinical use is limited to metastatic castration-resistant prostate cancer (mCRPC) who have progressed after the chemotherapy from the docetaxel because of its hydrophobicity and high toxicity as the less stability of its marketed formulation, Jevtana®. The nanomedicines of cabazitaxel have the potential to overcome the constraints of drug use and overcome taxane resistance. This review reports on the recent cabazitaxel-based drug delivery systems, explains the obstacles encountered in creating cabazitaxel nanoformulations and provides solutions to address these challenges.
Keywords:
Cabazitaxel, Cancer, Lipid nanoparticles, Nanocarriers, Polymeric nanoparticles, TaxanesDOI
https://doi.org/10.25004/IJPSDR.2022.140520References
Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration Approval Overview in Meta¬static Breast Cancer. J Clin Oncol [Internet] 2012 [cited 2022 May 12];30(14):1705. Available from: /pmc/articles/PMC3383116/
Bouchard H, Semiond D, Risse ML, Vrignaud P. Novel Taxanes: Cabazitaxel Case Study. Analog Drug Discov III [Internet] 2012 [cited 2022 May 12];319–41. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/9783527651085.ch13
Fojo AT, Menefee M. Microtubule targeting agents: basic mecha¬nisms of multidrug resistance (MDR). Semin Oncol [Internet] 2005 [cited 2022 May 12];32(6 Suppl 7):3. Available from: https:// pubmed.ncbi.nlm.nih.gov/16360716/
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Pre¬clinical profile of cabazitaxel. Drug Des Devel Ther 2014;8:1851–67.
Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthra¬cyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol [Internet] 2008 [cited 2022 May 12];35(2 Suppl 2). Available from: https://pubmed.ncbi.nlm.nih.gov/18410794/
Perez EA. Microtubule inhibitors: Differentiating tubulin-inhib¬iting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther [Internet] 2009 [cited 2022 May 12];8(8):2086–95. Available from: https://pubmed.ncbi.nlm.nih.gov/19671735/
(PDF) Stability-Indicating Rp-Hplc Method For The Determina¬tion Of Cabazitaxel [Internet]. [cited 2022 May 12];Available from: https://www.researchgate.net/publication/261075695_Stability- Indicating_rp-Hplc_method_for_the_determination_of_cabazitaxel
Chaurawal N, Misra C, Raza K. Lipid-based Nanocarriers loaded with Taxanes for the Management of Breast Cancer: Promises and Chal¬lenges. Curr Drug Targets [Internet] 2021 [cited 2022 May 12];22. Available from: https://europepmc.org/article/med/34431461
A Review On Taxanes: An Important Group Of Anticancer Compound Obtained From Taxus Sp | International Journal Of Pharmaceutical Sciences And Research [Internet]. [cited 2022 May 12];Available from: https://ijpsr.com/bft-article/a-review-on-taxanes-an-impor¬tant-group-of-anticancer-compound-obtained-from-taxus-sp/
Fitzpatrick JM, De Wit R. Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer. Eur Urol [Internet] 2014 [cited 2022 May 12];65(6):1198–204. Available from: http://www.europeanurology.com/article/S0302283813007379/fulltext
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Pre¬clinical profile of cabazitaxel. Drug Des Devel Ther 2014;8:1851–67.
Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwarts¬mann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol [Internet] 2008 [cited 2022 May 12];19(9):1547–52. Available from: https:// pubmed.ncbi.nlm.nih.gov/18436520/
De Bono JS, Oudard S, Ozguroglu M, Hansen S, MacHiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet (London, England) [Internet] 2010 [cited 2022 May 12];376(9747):1147–54. Available from: https://pubmed.ncbi.nlm.nih.gov/20888992/
Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magh¬erini E, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with meta¬static breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer [Internet] 2011 [cited 2022 May 12];47(7):1037–45. Available from: https://pubmed.ncbi. nlm.nih.gov/21339064/
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery- Vuillemin A, et al. Cabazitaxel: A novel microtubule inhibitor. Drugs 2011;71(10):1251–8.
Mita AC, Denis LJ, Rowinsky EK, De Bono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res [Internet] 2009 [cited 2022 May 12];15(2):723–30. Available from: https:// pubmed.ncbi.nlm.nih.gov/19147780/
Fda, Cder. Highlights Of Prescribing Information. [cited 2022 May 12];Available from: www.fda.gov/medwatch.
Luo D, Carter KA, Lovell JF. Nanomedical Engineering: shaping future nanomedicines. Wiley Interdiscip Rev Nanomed Nano-biotechnol [Internet] 2015 [cited 2022 May 12];7(2):169. Available from: /pmc/articles/PMC4308429/
Adekiya TA, Kondiah PPD, Choonara YE, Kumar P, Pillay V. A Review of Nanotechnology for Targeted Anti-schistosomal Therapy. Front Bioeng Biotechnol 2020;8:32.
Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003;92(7):1343–55.
Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine [Internet] 2010 [cited 2022 May 12];6(6):714–29. Available from: https://pubmed.ncbi.nlm.nih.gov/20542144/
Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm [Internet] 2008 [cited 2022 May 12];349(1–2):249–55. Available from: https://pubmed.ncbi.nlm.nih.gov/17875373/
Aydin O, Youssef I, Yuksel Durmaz Y, Tiruchinapally G, Elsayed MEH. Formulation of Acid-Sensitive Micelles for Delivery of Cabazitaxel into Prostate Cancer Cells. Mol Pharm [Internet] 2016 [cited 2022 May 12];13(4):1413–29. Available from: https://pubmed.ncbi.nlm. nih.gov/26977718/
Weiszhár Z, Czúcz J, Révész C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, tween-80 and tween-20. Eur J Pharm Sci 2012;45(4):492–8.
Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine [Internet] 2017 [cited 2022 Aug 22];12(17):2083. Available from: /pmc/articles/PMC5585843/
Song Y, Tian Q, Huang Z, Fan D, She Z, Liu X, et al. Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. Int J Nanomedicine [Internet] 2014 [cited 2022 May 12];9(1):2307. Available from:/pmc/articles/PMC4026555/
Zhu CJ, An CG. Enhanced antitumor activity of cabazitaxel targeting CD44+ receptor in breast cancer cell line via surface functionalized lipid nanocarriers. Trop J Pharm Res [Internet] 2017 [cited 2022 May 12];16(6):1383–90. Available from: https://www.ajol.info/ index.php/tjpr/article/view/158374
Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics 2019;11(3):1–22.
Reza AT, Nicoll SB. Characterization of novel photocrosslinked carboxymethylcellulose hydrogels for encapsulation of nucleus pulposus cells. Acta Biomater [Internet] 2010 [cited 2022 May 12];6(1):179–86. Available from: https://pubmed.ncbi.nlm.nih.gov/19505596/
Meng F, Hennink WE, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009;30(12):2180–98.
Xue P, Liu D, Wang J, Zhang N, Zhou J, Li L, et al. Redox-Sensitive Citronellol-Cabazitaxel Conjugate: Maintained in Vitro Cytotoxicity and Self-Assembled as Multifunctional Nanomedicine. Bioconjug Chem [Internet] 2016 [cited 2022 May 12];27(5):1360–72. Available from: ht tps://pubs.acs.org/doi/abs/10.1021/acs. bioconjchem.6b00155
Parhizkar E, Ahmadi F, Daneshamouz S, Mohammadi-Samani S, Sakhteman A, Parhizkar G. Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran. Anticancer Agents Med Chem [Internet] 2017 [cited 2022 May 12];17(11). Available from: https://pubmed.ncbi.nlm.nih.gov/28270079/
Sun B, Straubinger RM, Lovell JF. Current taxane formulations and emerging cabazitaxel delivery systems. Nano Res 2018;11(10):5193– 218.
Published
Abstract Display: 527 
PDF Downloads: 402 
